Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...

Gnosis, a Southern California-based diagnostic lab advancing women's health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for ...

(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

To evaluate the performance of a circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) liquid biopsy, LiquidHALLMARK (LHM), compared with tissue next-generation sequencing (NGS) and ...

A new blood test that uncovers hidden changes inside cancer cells could help doctors find the best treatments for children and young people with cancer.